Integrated genomic analyses of ovarian carcinoma Cancer Genome Atlas Research Network Nature 474 (7353), 609, 2011 | 7093 | 2011 |
The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4832 | 2018 |
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 2911 | 2018 |
Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2727 | 2018 |
Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2337 | 2018 |
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2188 | 2018 |
Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1772 | 2018 |
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1723 | 2017 |
Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1576 | 2015 |
Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1547 | 2011 |
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 1244 | 2015 |
Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 986 | 2018 |
Genomic and functional approaches to understanding cancer aneuploidy AM Taylor, J Shih, G Ha, GF Gao, X Zhang, AC Berger, SE Schumacher, ... Cancer cell 33 (4), 676-689. e3, 2018 | 958 | 2018 |
Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images J Saltz, R Gupta, L Hou, T Kurc, P Singh, V Nguyen, D Samaras, ... Cell reports 23 (1), 181-193. e7, 2018 | 913 | 2018 |
The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ... Cell reports 23 (1), 313-326. e5, 2018 | 895 | 2018 |
Adiposity and cancer at major anatomical sites: umbrella review of the literature M Kyrgiou, I Kalliala, G Markozannes, MJ Gunter, E Paraskevaidis, ... Bmj 356, 2017 | 871 | 2017 |
Comprehensive analysis of alternative splicing across tumors from 8,705 patients A Kahles, KV Lehmann, NC Toussaint, M Hüser, SG Stark, ... Cancer cell 34 (2), 211-224. e6, 2018 | 802 | 2018 |
Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma PA Vasey, GC Jayson, A Gordon, H Gabra, R Coleman, R Atkinson, ... Journal of the National Cancer Institute 96 (22), 1682-1691, 2004 | 800 | 2004 |
Pathogenic germline variants in 10,389 adult cancers K Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, ... Cell 173 (2), 355-370. e14, 2018 | 770 | 2018 |
Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines K Ellrott, MH Bailey, G Saksena, KR Covington, C Kandoth, C Stewart, ... Cell systems 6 (3), 271-281. e7, 2018 | 686 | 2018 |